Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 April 2025 | Story Anthony Mthembu | Photo Supplied
Kay-leigh van Rooyen
Kay-Leigh van Rooyen, Research Assistant at the University of the Free State (UFS), was one of sixteen individuals selected to participate in the 2024 Abe Bailey Travel Bursary.

As one of only sixteen recipients of the prestigious 2024 Abe Bailey Travel Bursary, Kay-Leigh van Rooyen, Research Assistant at the University of the Free State (UFS), recently returned from a life-changing journey across the United Kingdom. Representing the UFS on this esteemed programme, van Rooyen joined a cohort of emerging South African leaders in a transformative cultural and academic exchange. 

Reflecting on the experience, she described it as “nothing short of amazing.” 

“The experience was so much more than just visiting new places,” she said. “It was about engaging in meaningful conversations, forming lasting relationships, and gaining fresh perspectives on global issues.”

The Abe Bailey Travel Bursary aims to empower young South Africans through leadership development, cross-cultural exchange, and exposure to international dialogue. According to van Rooyen, this initiative was a powerful platform for personal growth, enabling her to see the world – and South Africa - through new lens.

“I learned the power of perspective - how others view our country, and how to understand global challenges from diverse vantage points,” she said. “I also realised that leadership is not about titles, but about influence and empathy.” 

 

A journey through the UK 

The bursary cohort convened in Cape Town on 23 November 2023 before departing for the UK, where they travelled from London to Edinburgh and back. The programme officially concluded on 18 December 2024/3. 

During the tour, the group visited iconic institutions such as the Royal Observatory in Greenwich, the British Library, the Francis Crick Institute, and the Houses of Parliament. For van Rooyen, the highlight was the opportunity to engage with thought leaders and changemakers. 

“One of the most memorable moments was having lunch in a chamber of the House of Lords at the Palace of Westminster with Lord Karan Bilimoria, the founder and chairman of Cobra Beer. The conversation was insightful and inspiring,” she said.  

 

A global stage for the UFS

Van Rooyen emphasised the professional impact of the experience, noting how it shaped her perspective on the role of academia in society. 

“This experience has changed the way I approach my work. I’ve developed a deeper appreciation for the importance of bridging the gap between academia and industry - especially how we can make research more practical and impactful,” she explained. 

She also highlighted the broader benefit for the UFS community. 

“Global engagements like these position the UFS as part of the international conversation. Our students and staff have valuable insights to share,  and we can learn so much from other institutions.” 

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation at the UFS and Chair of the university’s Abe Bailey Travel Bursary selection committee, echoed these sentiments. 

“The Travel Bursary so elegantly aligns with the vision and heart of the UFS - namely, to expose our students to a wider world and its global connections,” he said. 

 

Inspiring the next generation of UFS leaders 

Encouraging fellow UFS staff and students to apply for the bursary, van Rooyen emphasised the personal and professional rewards. 

“It challenges you to think critically, engage meaningfully, and build relationships with people you wouldn’t ordinarily meet,” she said. 

Prof Reddy praised van Rooyen for her achievements and representation of the UFS on a global stage.  

“Her experiences and insights demonstrate that she is an exceptional ambassador – not only as an Abe Bailey alumnus, but also as a symbol of the excellence the UFS strives for. We are extremely proud of Kay-Leigh and wish her well as we look forward to the great things that lie ahead for her.”

 

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept